Front-line therapy in polycythemia vera and essential thrombocythemia.
about
Guidelines for the management of myeloproliferative neoplasmsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FAdvances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.Vertebral artery thrombosis: a rare presentation of primary polycythaemia.Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosisPharmacological management of essential thrombocythemia.Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.Current and future treatment options for polycythemia vera.Mechanisms of thrombogenesis in polycythemia veraDiagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtableBleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.Primary thrombocytosis in children.Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.Ruxolitinib for the treatment of patients with polycythemia vera.How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.Essential thrombocythemia: Busulphan revisited.Effect of busulfan on JAK2V617F allele burden.
P2860
Q26778326-6F17D403-3C0B-4E4C-9F0C-8A6C7DF81569Q26795666-2B545C92-42A1-47D3-893D-54AA2E59406FQ33407110-668A5891-25E9-4200-869C-17A3E09FA8C5Q33691276-D475FDAC-5443-4562-954E-CB23D4333BE0Q33711653-512773ED-32B7-42C4-AD08-B588A3FCFE4AQ34344384-C19F5C16-B27F-4942-8869-92C3B55D8DD0Q34370771-80863772-A063-4B41-B62C-7C9CEF9A6B26Q35572748-169F6C32-AED7-4FE6-8F1F-99BF4DD180FBQ35738656-0AA2876A-4FFC-4271-AEB3-BF8A8179981DQ36266377-E8FC7714-BF3B-40D3-89B5-D4DEA94563A4Q36654317-D68AA480-22AD-4B52-89A7-17A97CA0805CQ37676262-950CB114-221C-49A2-A51B-A4CDB9AC8934Q37729428-90AA4A45-1A55-43E5-9BC7-82DD7B3D48A5Q38484321-CFD81316-21B1-41C5-A44D-03FD1F609D96Q38740700-7FC623C7-B481-491B-B52A-C59046214BA8Q38939571-57D71289-2074-424A-9842-076CE271CB90Q39661740-E1FAF0F5-F249-4F05-B9D0-534A8AA0DA5AQ40906382-200D7ED0-605E-497C-871D-31133B5FF86FQ42423798-D3D54918-C23E-4AB1-99B0-681D4D315659
P2860
Front-line therapy in polycythemia vera and essential thrombocythemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Front-line therapy in polycythemia vera and essential thrombocythemia.
@en
type
label
Front-line therapy in polycythemia vera and essential thrombocythemia.
@en
prefLabel
Front-line therapy in polycythemia vera and essential thrombocythemia.
@en
P2093
P1433
P1476
Front-line therapy in polycythemia vera and essential thrombocythemia.
@en
P2093
Guido Finazzi
Maria Chiara Finazzi
Tiziano Barbui
P304
P356
10.1016/J.BLRE.2012.06.002
P577
2012-07-10T00:00:00Z